Gene Regulation by Thiazolidinediones

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of rosiglitazone on the genes of the colon

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: James Lewis
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: 2,4-thiazolidinedione; Rosiglitazone

Criteria

Inclusion Criteria:

• Capable of giving informed consent

• Agrees to use a barrier method of birth control for the duration of the study

Exclusion Criteria:

• History of inflammatory bowel disease

• Has taken prescription or over the counter medications in the two weeks prior to enrollment

• History of diabetes, heart failure, angina, hypertension, coronary heart disease, cancer, bleeding disorder, HIV, AIDS

• Fasting LDL >160 mg/dl

• History of smoking in the year prior to enrollment

• Pregnant or breastfeeding